DSM and Crucell sign PER.C6(R) licence agreements

Published: 19-Dec-2008
Ingredients Research & Development Pharmaceutical

DSM Biologics, a division of DSM Pharmaceutical Products, and Dutch biotechnology company Crucell have signed commercial licence agreements with Hungary-based Gedeon Richter and GSK, which will allow both companies to develop biopharmaceuticals on the PER.C6(R) platform.


DSM Biologics, a division of DSM Pharmaceutical Products, and Dutch biotechnology company Crucell have signed commercial licence agreements with Hungary-based Gedeon Richter and GSK, which will allow both companies to develop biopharmaceuticals on the PER.C6(R) platform.

Financial terms were not disclosed.

Crucell's PER.C6(R) technology platform has been developed for the large-scale manufacture of biopharmaceutical products such as recombinant proteins including monoclonal antibodies. The company says the strengths of PER.C6(R) lie in its excellent safety profile, scalability and productivity under serum-free culture conditions.

Gedeon Richter will develop and produce "certain biopharmaceuticals" on the PER.C6(R) platform, while GSK will research a recombinant protein.

Karen King, president of DSM Biologics, said: "The PER.C6(R) production technology continues to surpass our expectations as a robust manufacturing platform with its ever extending and global reach into the r&d departments of major healthcare players."

  • Companies:
  • dsm-firmenich
See more

You may also like

Ingredients

dsm-firmenich showcases excipient and sustainability solutions at CPHI Milan

Read more
The company will present its range of solutions designed to boost patient compliance, while also exhibiting its pharma-grade CBD ingredient

Trending Articles

  1. Sartorius Stedim Biotech supports bioprocess development with new Innovation Centre The Massachusetts, US-based Centre for Bioprocess Innovation is a collaborative space designed to develop and optimise biomanufacturing processes
  2. Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
  3. Steritas and argenx join forces to advance steroid-sparing therapeutic development With the help of Steritas' STOX Suite, argenx aims to develop antibody-based therapeutics for immune diseases, potentially allowing patients to move away from chronic steroid usage
  4. Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)

Upcoming event

CPhI Middle East

10–12 December 2024 | Conference | Riyadh, Saudi Arabia See all

You may also like

Ingredients

dsm-firmenich showcases excipient and sustainability solutions at CPHI Milan

The company will present its range of solutions designed to boost patient compliance, while also exhibiting its pharma-grade CBD ingredient
Ingredients

The roadmap to success in the cannabinoid drug development journey

The key to success in the development and registration of cannabinoid-based medicines hinges on choosing a GMP-certified high-purity active ingredient that is of natural origin and supported by regulatory documentation. Drug developers looking to take product development further still should also consider patient-centricity during formulation and strategies to boost the efficacy of cannabinoids by optimising their bioavailability profile
Ingredients

What role can CBD play to support mental health?

Talking to Dr Kevin Robinson (KSR), DSM’s Clinical Project Scientist, Mariana Coelho (MC), shares the latest scientific findings behind CBD and how it could help to support mental health and well-being on a global scale, especially as the demand for viable treatments continues to grow
Ingredients

CBD: the new frontier in medical science

Early stage drug development plays an important role in expanding treatment options that will support the health of patients globally. To create bespoke drug products, it is important to explore and understand the benefits of new actives emerging on the market, such as cannabidiol (CBD), explains Kelsey Achenbach, Senior Director, Pharma and Medical Nutrition at DSM
Ingredients

Humanetics acquires all legal assets of DSM radioprotective API

All patents, trademarks, trade secret manufacturing processes of the API for BIO 300 have been sold to US-based Humanetics
Ingredients

DSM at CPhI: the rapidly evolving role of vitamins and lipids in disease management

Royal DSM, a global science-based company active in nutrition, health and sustainable living, invites you to discover the evolving role of vitamins and lipids in pharmaceutical applications at CPhI Worldwide 2018
Ingredients

The increasing importance of drug-nutrient interactions

Emerging scientific evidence suggests that micronutrient intake in higher doses holds promise for roles beyond currently recognised health effects for selected individuals and population groups
Subscribe now